A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

Completed · Phase 4 · Has a placebo group

Conditions studied: Erectile Dysfunction, Prostate Cancer

In brief

The purpose of the study is to compare the safety and effectiveness of Prograf in the prevention of erectile dysfunction in men after a radical prostatectomy.

Key facts

Study ID

NCT00106392

Run by

Astellas Pharma Inc

People needed

131

Starts

2005-02-01

Expected to finish

2008-11-01

Last updated by the study team

2010-11-23

Who can join

Age: any, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male scheduled to undergo bilateral nerve sparing radical prostatectomy for prostate cancer.

You may not qualify if…

• Patient is > 65 years of age
• Patient has been diagnosed with Type 1 or Type 2 diabetes
• Patient is actively smoking on a daily basis

Where it is running

• Study site — Ann Arbor, Michigan, United States
• Study site — New York, New York, United States
• Study site — New York, New York, United States
• Study site — Cleveland, Ohio, United States
• Study site — Nashville, Tennessee, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.